AXA purchased a new position in Natera Inc (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 167,715 shares of the medical research company’s stock, valued at approximately $4,626,000. AXA owned about 0.24% of Natera as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. TD Asset Management Inc. purchased a new stake in shares of Natera in the 2nd quarter worth approximately $477,000. Asymmetry Capital Management L.P. boosted its stake in Natera by 615.4% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 217,899 shares of the medical research company’s stock valued at $6,010,000 after purchasing an additional 187,441 shares during the last quarter. Allianz Asset Management GmbH boosted its stake in Natera by 4.5% during the 2nd quarter. Allianz Asset Management GmbH now owns 589,036 shares of the medical research company’s stock valued at $16,246,000 after purchasing an additional 25,334 shares during the last quarter. Dupont Capital Management Corp boosted its stake in Natera by 78.6% during the 2nd quarter. Dupont Capital Management Corp now owns 51,953 shares of the medical research company’s stock valued at $1,433,000 after purchasing an additional 22,866 shares during the last quarter. Finally, Envestnet Asset Management Inc. purchased a new stake in Natera during the 2nd quarter valued at $377,000. Institutional investors own 94.95% of the company’s stock.
In other Natera news, CTO Jonathan Sheena sold 1,033 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total value of $30,473.50. Following the completion of the sale, the chief technology officer now owns 241,937 shares in the company, valued at approximately $7,137,141.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 4,032 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $32.01, for a total value of $129,064.32. Following the completion of the sale, the chief financial officer now owns 32,878 shares of the company’s stock, valued at approximately $1,052,424.78. The disclosure for this sale can be found here. Insiders have sold a total of 438,953 shares of company stock worth $13,886,921 over the last three months. Insiders own 9.29% of the company’s stock.
Shares of NASDAQ NTRA traded up $1.47 during midday trading on Friday, hitting $37.06. 597,592 shares of the stock traded hands, compared to its average volume of 616,144. The firm has a 50-day moving average of $33.11 and a two-hundred day moving average of $26.13. The firm has a market capitalization of $2.39 billion, a P/E ratio of -17.24 and a beta of 1.42. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54. Natera Inc has a one year low of $11.08 and a one year high of $37.42.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09. The firm had revenue of $74.36 million for the quarter, compared to analysts’ expectations of $66.77 million. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The company’s revenue was up 17.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.62) EPS. Equities analysts forecast that Natera Inc will post -2.1 earnings per share for the current fiscal year.
Several brokerages have commented on NTRA. ValuEngine downgraded Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Canaccord Genuity reiterated a “buy” rating and set a $44.00 target price on shares of Natera in a research note on Wednesday, September 25th. Piper Jaffray Companies increased their target price on Natera from $32.00 to $45.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. Finally, Craig Hallum increased their target price on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Natera has a consensus rating of “Buy” and a consensus target price of $36.00.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.